Autopsy report · NCT01272141

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

“Slow accrual, Funding stopped”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Emory University

Sponsor type

University, hospital or other

Conditions

Breast Neoplasms; Breast Cancer; Cancer of the Breast

Interventions

Lapatinib and Everolimus

Participants

5

Sites

3

Countries

United States

Trials that died the same way

• Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
  “slow accrual; insufficient funding to continue to accrue” (91% match in meaning)
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
  “Limited funding, slow accrual” (88% match in meaning)
• Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
  “Slow accrual and lack of funding” (85% match in meaning)
• Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
  “Lack of funding and slow accrual” (79% match in meaning)
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
  “Slow accrual and funding limitations.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.